Case series of glans injuries during voluntary medical male circumcision for HIV prevention - eastern and southern Africa, 2015-2018.
Amputation
HIV
Intraoperative complications
Male circumcision
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
25 Apr 2020
25 Apr 2020
Historique:
received:
06
11
2019
accepted:
08
04
2020
entrez:
27
4
2020
pubmed:
27
4
2020
medline:
5
3
2021
Statut:
epublish
Résumé
Male circumcision confers partial protection against heterosexual HIV acquisition among men. The President's Emergency Plan for AIDS Relief (PEPFAR) has supported > 18,900,000 voluntary medical male circumcisions (VMMC). Glans injuries (GIs) are rare but devastating adverse events (AEs) that can occur during circumcision. To address this issue, PEPFAR has supported multiple interventions in the areas of surveillance, policy, education, training, supply chain, and AE management. Since 2015, PEPFAR has conducted surveillance of GIs including rapid investigation by the in-country PEPFAR team. This information is collected on standardized forms, which were reviewed for this analysis. Thirty-six GIs were reported from 2015 to 2018; all patients were < 15 years old (~ 0·7 per 100,000 VMMCs in this age group) with a decreasing annual rate (2015: 0.7 per 100,000 VMMCs; 2018: 0.4 per 100,000 VMMC; p = 0.02). Most (64%) GIs were partial or complete amputations. All amputations among 10-14 year-olds occurred using the forceps-guided (FG) method, as opposed to the dorsal-slit (DS) method, and three GIs among infants occurred using a Mogen clamp. Of 19 attempted amputation repairs, reattached tissue was viable in four (21%) in the short term. In some cases, inadequate DS method training and being overworked, were found. Following numerous interventions by PEPFAR and other stakeholders, GIs are decreasing; however, they have not been eliminated and remain a challenge for the VMMC program. Preventing further cases of complete and partial amputation will likely require additional interventions that prevent use of the FG method in young patients and the Mogen clamp in infants. Improving management of GIs is critical to optimizing outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Male circumcision confers partial protection against heterosexual HIV acquisition among men. The President's Emergency Plan for AIDS Relief (PEPFAR) has supported > 18,900,000 voluntary medical male circumcisions (VMMC). Glans injuries (GIs) are rare but devastating adverse events (AEs) that can occur during circumcision. To address this issue, PEPFAR has supported multiple interventions in the areas of surveillance, policy, education, training, supply chain, and AE management.
METHODS
METHODS
Since 2015, PEPFAR has conducted surveillance of GIs including rapid investigation by the in-country PEPFAR team. This information is collected on standardized forms, which were reviewed for this analysis.
RESULTS
RESULTS
Thirty-six GIs were reported from 2015 to 2018; all patients were < 15 years old (~ 0·7 per 100,000 VMMCs in this age group) with a decreasing annual rate (2015: 0.7 per 100,000 VMMCs; 2018: 0.4 per 100,000 VMMC; p = 0.02). Most (64%) GIs were partial or complete amputations. All amputations among 10-14 year-olds occurred using the forceps-guided (FG) method, as opposed to the dorsal-slit (DS) method, and three GIs among infants occurred using a Mogen clamp. Of 19 attempted amputation repairs, reattached tissue was viable in four (21%) in the short term. In some cases, inadequate DS method training and being overworked, were found.
CONCLUSION
CONCLUSIONS
Following numerous interventions by PEPFAR and other stakeholders, GIs are decreasing; however, they have not been eliminated and remain a challenge for the VMMC program. Preventing further cases of complete and partial amputation will likely require additional interventions that prevent use of the FG method in young patients and the Mogen clamp in infants. Improving management of GIs is critical to optimizing outcomes.
Identifiants
pubmed: 32334596
doi: 10.1186/s12894-020-00613-6
pii: 10.1186/s12894-020-00613-6
pmc: PMC7183662
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45Références
BJU Int. 2005 Nov;96(7):1109-13
pubmed: 16225538
J Pediatr Urol. 2013 Dec;9(6 Pt A):763-8
pubmed: 23137994
BMC Health Serv Res. 2015 Jun 18;15:235
pubmed: 26084777
Korean J Urol. 2011 Feb;52(2):147-9
pubmed: 21379434
MMWR Morb Mortal Wkly Rep. 2018 Mar 23;67(11):337-339
pubmed: 29565839
MMWR Morb Mortal Wkly Rep. 2016 Jan 22;65(2):36-7
pubmed: 26797167
BMC Urol. 2019 Jul 11;19(1):65
pubmed: 31296191
J Urol. 1997 Nov;158(5):1946-7
pubmed: 9334645
Urol Ann. 2014 Jan;6(1):85-7
pubmed: 24669132
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003362
pubmed: 19370585
Pediatrics. 2012 Sep;130(3):e756-85
pubmed: 22926175
Lancet. 2007 Feb 24;369(9562):643-56
pubmed: 17321310
Urology. 2011 Jun;77(6):1472-3
pubmed: 21256558